On Thursday, April 24th, Dr. Eric Crombez, Ultragenyx’s chief medical officer and executive vice president, was sworn in as a member of the Massachusetts Rare Disease Advisory Council (RDAC).
Surrounded by colleagues and his husband Ryan, Dr. Crombez officially joined the RDAC, a group established in 2020 with a mission to “provide guidance and recommendations on rare disease incidence and the status and needs of the rare disease community to the governor, the legislature, and the department of public health with the goal of improving the lives of people impacted by a rare disease in the Commonwealth.” Currently, 28 other states also have RDACs.
Dr. Crombez was appointed by Governor Maura Healy and is expected to serve on the council for 3 years.
“I’m honored to serve on the council, and I am grateful to Governor Healey for the appointment,” said Dr. Crombez. “My academic, clinical and industry career has been focused on the development of new treatments for people living with rare diseases and I hope to be able to contribute to all of the great progress that the RDAC has made since forming.”
“At Ultragenyx we are committed to the advancement of innovative and life-changing treatments for rare diseases. We recognize the importance of engaging those living with rare diseases and their caregivers to understand how these diseases affect their lives and to inform our efforts to develop treatments that will meaningfully benefit them,” continued Dr. Crombez. “Massachusetts has been very supportive of this work and the council is another example of the state continuing to demonstrate a commitment to rare disease patients and families.”
More about Dr. Crombez
Dr. Crombez joined Ultragenyx following the acquisition of Dimension Therapeutics in November 2017. As Chief Medical Officer and Executive Vice President, Dr. Crombez is responsible for strategic leadership of the clinical development and translational research programs, and oversees global development functions. Previously, he worked at Shire in its Human Genetics Therapy business unit. Dr. Crombez serves on the board of Abeona Therapeutics and Epicrispr Biotechnologies.
Dr. Crombez is a board-certified clinical geneticist and completed residencies in pediatrics and medical genetics and a fellowship in clinical biochemical genetics at the UCLA School of Medicine. Dr. Crombez obtained his B.S. degree in biology from the University of Michigan, Ann Arbor, and his M.D. degree from Wayne State University School of Medicine, Detroit.
To learn more about Dr. Crombez and meet other members of the Ultragenyx management team visit: Leadership—Ultragenyx.
